Mesenchymal Cell Potency Assay via TGFβ1 Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for potency testing of cellular therapy products, particularly those involving mesenchymal lineage precursor or stem cells, face challenges in accurately assessing biological activity and therapeutic efficacy due to the complexity and heterogeneity of these products.
Innovation Solution
An in vitro method is developed to select human mesenchymal precursor cells (MPCs) based on their ability to release a specific amount of TGFβ1 into the culture medium, with a threshold of at least 2800 pg/10^6 cells, indicating biological activity or therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If biologic characterization methods are used to assess potency, then biological activity and therapeutic efficacy are accurately measured, but the complexity and heterogeneity of cellular therapy products make identification of relevant biologic activities difficult
Solution Approach 1:
The patent segments the complex biologic characterization into distinct functional assays: a proliferation assay to measure cell division capacity and a differentiation assay to measure lineage commitment. This segmentation allows each assay to target specific biologic activities independently, making the overall complexity manageable while maintaining measurement precision for potency assessment
Solution Approach 2:
The patent develops universal assay platforms that can evaluate multiple biologic activities across different cellular therapy product types. The proliferation and differentiation assays are designed to be applicable to various stem cell and progenitor cell products, providing a multi-functional solution that addresses potency measurement across diverse cell therapies without requiring product-specific customization for each assay
2Quantity of substance
If physiochemical parameters are used for product characterization, then identification and quantification of active substance and impurities is achieved, but the ability to confirm biological activity and potency is lost
Solution Approach 1:
The patent introduces biologic activity assays as intermediary measurements that bridge physiochemical characterization and therapeutic efficacy. The proliferation and differentiation assays serve as mediators that translate physical cell properties into functional biological outcomes, confirming that the characterized cell product actually exhibits the expected biological activities and potency rather than merely possessing correct physiochemical properties
3Reliability
If potency testing is required for each batch of cellular therapy product, then therapeutic efficacy is ensured, but the time and resources required for batch evaluation increase
Solution Approach 1:
The patent implements preliminary characterization during the manufacturing process itself, where proliferation and differentiation assays are performed on process samples at defined stages. This preliminary action provides early indicators of batch quality and potency, allowing potential issues to be detected before final batch completion, thereby reducing the time and resources needed for post-manufacturing batch release testing
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3A~3B
AI summary
The present invention relates to a method for determining the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor cells or stem cells the based on their released TGF-9 levels in culture. The present invention also relates to isolated populations of mesenchymal lineage precursor cells or stem cells selected based on the level of TGF-9 levels released by such cells in culture. The present invention further relates to treatment of a subject suffering from a degenerative disc disease by administering such selected cell populations.